MIH
TEVA icon

Meitav Investment House’s Teva Pharmaceuticals TEVA Stock Holding History

Meitav Investment House’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,305,674
Closed -$44.9M – 344
2023
Q4 		$44.9M Buy
4,305,674
+1,950,500
+83% +$18.2M 0.66% 45
2023
Q3 		$24.3M Sell
2,355,174
-1,420,000
-38% -$13.2M 0.39% 71
2023
Q2 		$28.7M Buy
3,775,174
+889,432
+31% +$7.21M 0.46% 65
2023
Q1 		$25.5M Buy
2,885,742
+220,384
+8% +$2.18M 0.44% 70
2022
Q4 		$24.9M Sell
2,665,358
-12,000
-0.4% -$105K 0.43% 68
2022
Q3 		$20.9M Buy
2,677,358
+1,474,889
+123% +$13M 0.37% 70
2022
Q2 		$9.01M Buy
1,202,469
+3,000
+0.3% +$26.1K 0.15% 114
2022
Q1 		$11.2M Buy
1,199,469
+683,969
+133% +$5.71M 0.17% 110
2021
Q4 		$4.13M Sell
515,500
-654,044
-56% -$5.9M 0.07% 169
2021
Q3 		$11.4M Buy
1,169,544
+409,128
+54% +$3.83M 0.19% 116
2021
Q2 		$7.53M Buy
760,416
+87,839
+13% +$930K 0.19% 102
2021
Q1 		$7.76K Buy
672,577
+24,017
+4% +$275K 0.22% 98
2020
Q4 		$6.26M Buy
648,560
+7,700
+1% +$73.8K 0.25% 81
2020
Q3 		$5.77M Buy
640,860
+147,167
+30% +$1.56M 0.29% 76
2020
Q2 		$6.08M Buy
493,693
+175,469
+55% +$1.98M 0.36% 67
2020
Q1 		$2.84M Buy
318,224
+307,924
+2,990% +$3.15M 0.21% 76
2019
Q4 		$100K Sell
10,300
-1,000
-9% -$8.93K 0.01% 418
2019
Q3 		$79K Sell
11,300
-334,394
-97% -$2.56M 0.01% 436
2019
Q2 		$3.19M Sell
345,694
-5,029
-1% -$60.6K 0.21% 64
2019
Q1 		$5.5M Sell
350,723
-84,413
-19% -$1.49M 0.31% 55
2018
Q4 		$6.71M Buy
435,136
+347,866
+399% +$7.13M 0.42% 60
2018
Q3 		$1.87M Buy
87,270
+47,307
+118% +$1.1M 0.09% 145
2018
Q2 		$956K Sell
39,963
-92,841
-70% -$1.89M 0.04% 212
2018
Q1 		$2.27M Sell
132,804
-131,907
-50% -$2.58M 0.12% 88
2017
Q4 		$5.02M Buy
+264,711
New +$3.98M 0.29% 69

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Meitav Investment House's TEVA Position: Q1 2024 in Review

Meitav Investment House sold out of Teva Pharmaceuticals (TEVA) in Q1 2024, closing a stake of 4,305,674 shares — an estimated $44.9M sold.

Meitav Investment House first reported a position in TEVA in Q4 2017 and held it in 25 quarters. The position peaked at $44.9M in Q4 2023. 481 funds tracked by Wall St. Rank hold TEVA as of Q1 2024.

  • Meitav Investment House reported no remaining Teva Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Meitav Investment House sold 4,305,674 Teva Pharmaceuticals shares in Q1 2024, an estimated $44.9M.
  • Meitav Investment House first reported a position in Teva Pharmaceuticals in Q4 2017 and held it in 25 quarters.
  • Meitav Investment House's Teva Pharmaceuticals position peaked at $44.9M in Q4 2023.
  • 481 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2024.

Based on Meitav Investment House's 13F filing for Q1 2024, filed 1 May 2024.